Israeli Biotech Company AEBi Claims Complete Cure For Cancer Could Be Ready Within A Year

Could there be an available cure for cancer soon? An Israeli biotech company is optimistic this could happen soon. It said a complete cure for the disease is within reach and could finally be offered within a year.

MuTaTo

The treatment called MuTaTo (multi-target toxin) essentially works as a cancer antibiotic. It used a combination of several peptides — chain of amino acids — to target and kill cancer cells, eliminating risk of evasion through mutation.

Based on preliminary results of the mice study, researchers at Accelerated Evolution Biotechnologies (AEBi), where the treatment is being developed, anticipate a complete cure for cancer within a year.

"Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market," AEBi's chairman of the board of directors Dan Aridor said. "Our solution will be both generic and personal."

When Will Treatment Become Available?

AEBi explained "complete cure for cancer" is having the complete solution ready for first testing in humans. This means it could still take years before cancer patients can use the treatment, even if it indeed works.

AEBi has not yet published clinical evidence that shows the treatment works in humans. The company has only so far finished the first exploratory mice experiment, and bringing the cancer drug from "mouse to market" could still take six to seven years, even if the drugmaker receives green light from the FDA to speed up drug development.

Hope For Cancer Patients

A promising cure for cancer nonetheless offers hope for millions who are diagnosed with the deadly disease.

Cancer is one of the leading causes of deaths worldwide. Figures from the National Cancer Institute show there were 14.1 million new cases of cancer in 2012. This number is expected to rise to 23.6 million by the year 2030.

ⓒ 2024 TECHTIMES.com All rights reserved. Do not reproduce without permission.
Join the Discussion
Real Time Analytics